Urgent.News

600+ sources. One page. See who else covered it.

Editions

Health & Medicine

Nirsevimab's RSV Protection Didn't Extend to Second Year

(MedPage Today) -- The monoclonal antibody nirsevimab (Beyfortus) consistently performed well against respiratory syncytial virus (RSV)-related hospitalization during infants' first year after receipt but without a benefit for other hospitalizations...

Nirsevimab's RSV Protection Didn't Extend to Second Year

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine